DadFinStart your free weekNovoCure Limited (NVCR) stock score
$14.58 ▲ +2.53% today
NovoCure Limited (NVCR) is a Medical Devices company in the Healthcare sector, listed in Switzerland. On DadFin's weekly run it scores 44.9 out of 100 on the Dad Score, a middling reading that places the business ahead of 45% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #471 of 974. Its strongest axis is valuation; its weakest are price action and risk.
Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →
The eight axes
Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.
Key numbers
What subscribers see on NVCR
- Value Score: is the price right for this business, the score the Value book is selected on.
- Trader Score: is it set up to move, refreshed every 15 minutes in the session.
- The full eight-axis breakdown, every input and its percentile.
- SEC filings, insider buying, earnings history and peers side by side.
- Whether it is in this week's published books, with the receipts.
Medical Devices peers
| Stock | Company | Dad Score | Band |
|---|---|---|---|
| ABT | Abbott Laboratories | 78.9 | good |
| MDT | Medtronic plc | 90.4 | strong |
| SYK | Stryker Corporation | 86.0 | strong |
| BSX | Boston Scientific Corporation | 94.3 | strong |
| EW | Edwards Lifesciences Corporation | 49.4 | middling |
| DXCM | DexCom, Inc. | 82.9 | good |
| GEHC | GE HealthCare Technologies Inc. | 94.5 | strong |
| PHG | Koninklijke Philips N.V. | 62.3 | middling |
Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.